Enable JavaScript to visit this website.

Today I am living with metastatic breast cancer

Clinical trials are still ongoing to determine if there is an effect on overall survival.

IBRANCE® is a prescription medicine that is taken in combination with either letrozole or fulvestrant, and is for women with hormone receptor-positive, HER2- metastatic breast cancer.
Hormone receptor-positive metastatic breast cancer includes estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) subtypes.

IBRANCE® is a prescription medicine that is taken in combination with either letrozole or fulvestrant, and is for women with hormone receptor-positive, HER2- metastatic breast cancer.

Learn More

INDICATIONS: IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with letrozole as the first hormonal based therapy in women who have gone through menopause, or fulvestrant in women with disease progression following hormonal therapy.

The effectiveness of IBRANCE plus letrozole is based on a study that measured progression-free survival. There is an ongoing study to find out how IBRANCE works in combination with letrozole over a longer period of time.

Eligible Patients Pay No More Than $10 Per Month* For IBRANCE

Limits, terms, and conditions apply. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Please visit PfizerCoPayOne.com or see savings card for complete terms and conditions. For any questions, please call 1-855-612-1951 or visit PfizerCoPayOne.com. Pfizer Inc, 235 East 42nd Street, New York, NY 10017.

Get To Know Women Taking IBRANCE
Support, Resources, And Insights To Help You Learn More About IBRANCE

IBRANCE Answers delivers facts and resources to help you understand more about IBRANCE and find helpful support throughout treatment.